Titanium Breast Marker Lawsuit (Biozorb Lawsuit)
Patients harmed by BioZorb implants may qualify for legal action. If you or a loved one suffered complications from a BioZorb marker, you could file a BioZorb lawsuit.
The titanium breast marker lawsuit focuses on severe health risks linked to this implant. Many patients report pain, infections, and migration of the marker. These issues often require additional surgeries.
We help victims hold manufacturers accountable. Our legal team offers a free case review to determine if you qualify. Contact us today to explore your legal options.
This is an Active Lawsuit
Key Titanium Breast Marker Lawsuit Takeaways
- BioZorb implants were designed to assist breast cancer patients, but post-market reports revealed serious complications, including device migration, infections, and chronic pain.
- Hologic faces lawsuits for failing to warn about BioZorb’s health risks before its medical device recall. Plaintiffs claim the company prioritized profit over patient safety.
- BioZorb lawsuit settlements may range from $100,000 to $500,000, with jury verdicts potentially exceeding $1 million, depending on injury severity and medical costs.
- BioZorb settlements may take months or years, with payouts expected in 2025 or 2026 if a global settlement is reached.
- Patients affected by BioZorb injuries can file an individual lawsuit or join a BioZorb class action lawsuit, depending on their case.
- To qualify for compensation, plaintiffs must prove they suffered serious side effects, such as severe pain, infections, or the need for surgical removal due to a BioZorb implant.
- A qualified BioZorb lawyer can provide a free case review, helping victims seek financial compensation for medical bills, lost wages, and long-term suffering.
BioZorb Lawsuit Updates (Timeline)
The BioZorb lawsuit is progressing, with key legal developments shaping the case. Courts have set trial dates, while plaintiffs continue to push for accountability. Lawsuits claim BioZorb implants cause serious complications, including infections and migration. Some victims seek settlements, while others prepare for trial. The timeline below highlights major updates, including court rulings, recall actions, and potential settlements. Staying informed is crucial for those affected. Follow the latest developments to understand what this means for your case.
Below, we provide the latest updates on Oxbryta’s recall, legal actions, and settlement progress. Stay informed about key events that may impact your eligibility for compensation.
February 2025
A judge scheduled the BioZorb trial for September 8, 2025, which may influence future settlements. No new discovery will be allowed. Plaintiffs’ lawyers requested to reopen discovery for depositions related to the BioZorb recall. However, the court denied this, stating that the recall happened too late to impact earlier trial preparations. This decision keeps the case on track for trial without additional delays.
Plaintiffs argue that Oxbryta increased red blood cell breakdown, worsening anemia and inflammation. The drug was recalled after reports linked it to worsened pain crises and multi-organ failure. Lawsuits allege patients were not properly warned about these risks.
January 2025
The FDA issued a warning letter stating that BioZorb implants fail to meet safety standards and lack proper testing on resorption. The agency also found that Hologic failed to assess BioZorb’s impact on cancer detection and radiation therapy, strengthening lawsuits against the company.
In a major legal victory, a judge denied Hologic’s request to dismiss a case, allowing a plaintiff to move forward with claims of severe complications. The ruling suggests Hologic failed to warn doctors about BioZorb’s risks, reinforcing claims in the growing titanium breast marker lawsuit.
December 2024
The BioZorb titanium breast marker lawsuits are advancing quickly. A judge selected four cases for early trials, with the first set for September 8, 2025. These cases involve severe complications, including infections, pain, and failed absorption.
A new lawsuit filed by five plaintiffs alleges Hologic misled patients and failed to warn about risks. Meanwhile, discussions around a BioZorb class action lawsuit (MDL) continue as more victims seek justice.
The FDA’s recall and increased oversight highlight systemic failures in medical device regulation, strengthening claims against Hologic. These developments push the litigation forward.
October 2024
The FDA issued a Safety Communication advising against the use of BioZorb breast markers due to serious risks like migration, pain, and infection. This followed an increase in reported complications, reinforcing concerns about the device’s failure to meet safety standards.
Days earlier, Hologic announced an urgent recall of all unused BioZorb Markers, citing severe adverse effects, including fluid buildup, rashes, and surgical removal risks. This recall confirmed long-standing safety concerns and is expected to impact Hologic’s financial and legal future as lawsuits continue to grow.
September 2024
A federal judge denied Hologic’s motion for summary judgment, allowing BioZorb lawsuits to proceed. This ruling confirms that plaintiffs can pursue claims of harm caused by the device’s defective design.
The decision puts added pressure on Hologic, forcing the company to either prepare for lengthy litigation or consider settlements to avoid prolonged legal battles. This marks a significant step for plaintiffs seeking justice for the severe complications linked to BioZorb breast markers.
August 2024
The BioZorb lawsuits are not a formal class action (MDL) but are consolidated in federal court in Massachusetts. Judge Allison D. Burroughs has set a bellwether trial plan, selecting representative cases to proceed first.
These early trials, set for July 2025, will test how juries respond to claims that the BioZorb marker was defectively designed. Their outcomes will likely influence liability findings and potential settlement amounts for other plaintiffs.
June 2024
Experts have raised concerns that the BioZorb Marker lacked proper real-world testing before its release. During a healthcare conference, panelists emphasized the need for more rigorous pre-market evaluations to account for diverse patient scenarios.
This discussion highlights potential flaws in the medical device approval process, questioning whether regulatory agencies should enforce stricter testing requirements. These concerns support plaintiffs’ claims that BioZorb was introduced without fully understanding its long-term risks.
May 2024
The BioZorb recall raises concerns about the FDA’s 510(k) approval process, which allows devices to reach the market without clinical trials if they are deemed “substantially equivalent” to existing products. Many argue that this fast-track system fails to protect patients, especially for complex devices like BioZorb.
Plaintiffs claim Hologic used this process to bypass critical safety testing, prioritizing speed over patient well-being. While the FDA’s approval may serve as Hologic’s defense, the shifting regulatory stance strengthens lawsuits that argue the device was never properly vetted.
On May 1, 2024, the FDA classified the BioZorb recall as Class I, the most serious level, indicating a high risk of severe injury or death. This designation escalates scrutiny and supports claims that BioZorb posed significant dangers to patients.
February 2024
Hologic issued a Medical Device Safety Notification, warning about potential risks with the BioZorb Marker, including migration and infection. This was the first public acknowledgment of safety concerns and set the stage for further investigations, a large-scale recall, and mounting lawsuits.
For many plaintiffs, this notice serves as early evidence that Hologic was aware of BioZorb’s risks before the full recall. It strengthens claims that the company failed to act quickly enough to protect patients from harm.
Table of Contents
What is BioZorb?
BioZorb devices are implantable radiographic markers used in breast cancer treatment. Surgeons place these soft tissue markers at the site of a tumor removal to help healthcare providers accurately target radiation therapy.
These implants consist of a bioabsorbable framework with titanium clips, designed to dissolve over time while leaving the clips behind for imaging. BioZorb LP Markers are a variation of these implants, used in similar procedures.
While intended to aid treatment, device migration and adverse events have been reported, with some patients experiencing severe pain and complications requiring further medical care.
What Is the BioZorb Lawsuit About?
BioZorb marker devices were developed to assist breast cancer patients undergoing radiation therapy by marking soft tissue sites after tumor removal. These implantable radiographic marker devices were promoted as tools to help surgeons improve cosmetic outcomes while ensuring precise treatment. However, many patients experienced complications, including device erosion, chronic pain, and scar tissue formation. Reports indicate that the device’s manufacturer, Focal Therapeutics, and later Hologic, failed to adequately test the product before widespread use.
As lawsuits mount, plaintiffs claim that BioZorb markers led to serious adverse events, including device breaking, migration, and infections. Some patients required future medical procedures to remove fragments embedded in breast tissue, leading to financial compensation claims for medical bills and ongoing treatment. Many filed lawsuits argue that the medical device litigation stems from Hologic’s failure to disclose risks, despite growing concerns from health care providers.
The FDA safety communication and voluntary recall confirmed the risks, strengthening claims against Hologic. The BioZorb recall lawsuit alleges that the company ignored red flags while aggressively marketing the product. BioZorb recall lawyers emphasize the role of medical records in proving negligence and helping victims seek justice. BioZorb attorneys continue to fight for victims facing serious injuries caused by this dangerous medical device.
Injuries and Complications Linked to BioZorb Markers
Patients who received a BioZorb implant expected a safe, effective breast biopsy marker to aid in radiation therapy. Instead, many have suffered serious complications that required additional medical procedures. Reports show device migration, infections, and chronic pain, leading to filed lawsuits against the device’s manufacturer. These claims are central to the titanium breast marker lawsuit, as victims seek financial compensation for medical bills and long-term suffering. The BioZorb recall lawsuit continues to grow as more patients come forward.
Infections and Severe Inflammation
Many breast cancer patients developed infections after a BioZorb marker was implanted. These infections caused severe pain, inflammation, and tissue damage, often requiring surgical removal of the device. Some cases led to adverse events, including abscesses and necrosis.
Fluid Buildup (Seroma Formation)
Fluid buildup around the BioZorb devices is a frequent issue. Patients reported seromas forming at the implantation site, causing discomfort and delaying healing. Healthcare providers often needed to drain the fluid, increasing the risk of infection.
Migration of the Marker in the Body
Device migration is a major concern in the BioZorb marker lawsuit. Some patients found that the BioZorb marker broke apart and shifted within their breast tissue, leading to further complications. This raised health risks and required additional procedures.
Skin Piercing and Disfigurement
Some patients reported BioZorb implants eroding through the skin, causing visible protrusions and disfigurement. This painful complication often necessitated immediate surgical removal and left permanent scars.
Long-Term Pain and Discomfort
Many lawsuits cite chronic pain linked to BioZorb complications. Patients experienced serious injury due to device erosion or inflammation, sometimes lasting years after the initial surgery.
Surgical Removal Risks and Scarring
For some, removing the dangerous medical devices required complex surgical procedures. The process often led to scarring, tissue damage, and financial burdens. Patients included in the BioZorb class action lawsuit argue that these risks were not properly disclosed.
This is an Active Lawsuit
Who Can File a BioZorb Lawsuit?
Patients who suffered BioZorb injuries may qualify for compensation. If a BioZorb marker was implanted and caused pain, infections, or other complications, you could have a valid claim. Many patient lawsuits argue that Hologic failed to warn about serious risks, leading to avoidable harm.
To file a claim, you must show that a surgeon implanted the device and that it caused health issues requiring medical treatment. Lawsuits seek compensation for medical bills, pain, and long-term effects. A BioZorb lawyer can review your case and determine eligibility.
Some victims file individual lawsuits, while others join a BioZorb settlement through a class action or mass tort. Unlike individual cases, a class action lawsuit combines similar claims, streamlining the BioZorb litigation. With the medical device recall, more victims are seeking justice. If you suffered complications, you may be entitled to a BioZorb lawsuit settlement.
How to File a Titanium Breast Marker Lawsuit
If you suffered serious complications from a BioZorb implant, you may be eligible to file a BioZorb lawsuit. The process starts by consulting a lawyer who specializes in medical device cases. Your legal team will review medical records, document BioZorb complications, and gather evidence of adverse events like device migration or infections.
Lawsuits seek compensation for medical costs, pain, and future care. Even if you have unused BioZorb markers, legal action may still apply. As BioZorb lawsuits grow, many victims pursue a BioZorb lawsuit settlement to cover damages caused by these BioZorb devices.
Potential BioZorb Lawsuit Settlements & Jury Verdicts
Settlement amounts in BioZorb lawsuits vary based on the severity of BioZorb complications. Plaintiffs with serious injuries that required surgical removal or led to long-term pain may receive higher payouts. Based on similar medical device recall cases, estimated BioZorb settlement amounts could range from $100,000 to $500,000 per claimant.
If trials result in jury verdicts, compensation could exceed $1 million, especially for cases involving device migration, infections, or device breaking inside the body. However, each case is unique, and settlement values depend on medical evidence and the impact on the victim’s life.
Get Legal Help for Your BioZorb Lawsuit
If you experienced complications from a BioZorb marker implanted during breast cancer treatment, you may be entitled to compensation. Many victims suffered device erosion, fluid buildup, and serious injury, requiring additional procedures.
Our team connects you with experienced BioZorb recall lawyers who understand BioZorb litigation and fight for the maximum BioZorb settlement. Don’t wait—file a BioZorb lawsuit today to explore your legal options. A BioZorb lawyer can help you seek justice for your pain, medical costs, and long-term health risks.
This is an Active Lawsuit
Frequently Asked Questions (FAQs) About the BioZorb Lawsuit
Many patients with a BioZorb implant have experienced serious complications, leading them to consider legal action. If you believe a BioZorb marker implanted during your breast cancer treatment caused harm, you may have a claim. Below, we answer common questions about the BioZorb marker lawsuit, the medical device recall, and your legal rights.
A defective BioZorb marker may cause pain, swelling, infections, device migration, and adverse events such as fluid buildup or tissue damage. Some patients report device breaking or failing to dissolve, requiring additional treatment.
Yes, the BioZorb marker lawsuit gained traction after the voluntary recall issued by Hologic. The medical device recall came after reports of serious complications, leading to increased scrutiny by healthcare providers and the FDA.
Some patients found that their BioZorb LP markers did not dissolve as expected, causing chronic pain and requiring surgical removal. If this happened to you, you may qualify to file a BioZorb lawsuit for medical expenses and suffering.
Some patients found that their BioZorb LP markers did not dissolve as expected, causing chronic pain and requiring surgical removal. If this happened to you, you may qualify to file a BioZorb lawsuit for medical expenses and suffering.
While there is no certified BioZorb class action lawsuit yet, many BioZorb lawsuits have been consolidated into multidistrict litigation (MDL). This allows multiple claims to proceed efficiently while still recognizing individual damages.
If you experienced complications from a BioZorb marker implanted during a breast biopsy marker procedure, you may qualify for a marker lawsuit. A BioZorb lawyer can review your medical records and determine if you are eligible for compensation.
Most BioZorb litigation attorneys work on a contingency fee basis, meaning you pay nothing upfront. If your case is successful, legal fees are deducted from your BioZorb lawsuit settlement. This ensures that victims can seek justice without financial risk.
This is an Active Lawsuit
